- ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option<figure><div><img src="https://imgproxy.divecdn.com/s1OP69WlFaq8Ze7MFeyEVPnIDEywrEml5dBx5ZtKpus/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjY1Nzc4NTU4XzEua…BioPharma Dive · 1mo ago↗ source
- STAT+: UnitedHealthcare’s lactation billing feud, and fake strokesThe biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.STAT · 1mo ago↗ source
- STAT+: Novo underwhelmed by drug it once fought Pfizer forRevolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech newsSTAT